Therapy for Metastatic breast cancer based on micro RNA silencing

转移性乳腺癌患者的治疗选择严重有限，最终依赖于 姑息治疗代表了一种未得到满足的临床需求。以前的研究已经证明，microRNAs在 在包括乳腺癌转移在内的转移形成过程中起着重要作用。考虑到...的匮乏 乳腺癌转移患者的选择，在这项建议中，我们重点针对miR-10b 被证明是转移扩散的罪魁祸首。虽然先前的研究表明miR-10b推动了入侵 和原发肿瘤癌细胞的迁移，我们最近的发现表明，在转移细胞中 也对细胞的存活和增殖负责，而转移细胞的存活关键取决于 MiR-10b的高表达。这一发现成为我们治疗策略的基石，旨在 特异性根除转移性肿瘤细胞。这将使用能够成像的模块化纳米片来完成， 分布于肺、肝、骨或脑转移。这些纳米颗粒由磁性纳米颗粒组成 携带抑制microRNA-10b的锁定核酸(LNA)寡核苷酸。靶向共轭基团 到纳米颗粒，促进它们在远处转移部位的积聚。在此之前我们已经演示了 论证了所提出的方法的可行性。将纳米地毯输送到已经形成的淋巴结 转移通过抑制肿瘤细胞的增殖和引起 细胞凋亡，这是一种以前从未描述过的现象。当用纳米地毯治疗的时候 结合小剂量的常规化疗(阿霉素)，出现了退行性和永久性。 消除淋巴结或肺转移，即使在停止治疗后也不会复发。不像 在常规化疗中，这种治疗方案与动物发病率/死亡率无关。在……里面 目前的应用我们建议将miR10b抑制纳米片与低剂量联合使用 针对远处器官转移的乳腺癌的化疗(如有必要)。非侵入性 成像将用于评估纳米地毯的交付情况。如果成功，这种方法可能会成为一种生活- 延长(可能是挽救生命)晚期转移性疾病患者的替代方案 抢救疗法是目前唯一的选择。

Treatment options for patients with metastatic breast cancer are severely limited and ultimately rely on palliative care representing an unmet clinical need. Previous studies have demonstrated that microRNAs play a significant role in the formation of metastasis including those from breast cancer. Considering the paucity of options for patients with metastasis from breast cancer, in this proposal we focused on targeting miR-10b proven to be responsible for metastatic spread. While previous studies showed that miR-10b drives invasion and migration of cancer cells from primary tumors, our recent discovery demonstrated that in metastatic cells it is also responsible for cell viability and proliferation and that survival of metastatic cells crucially depends on the high level of miR-10b expression. This discovery formed a cornerstone of our therapeutic strategy aimed at specific eradication of metastatic tumor cells. This will be done using imaging-capable modular nanodrugs, which distribute to lung, liver, bone, or brain metastases. These nanodrugs consist of magnetic nanoparticles that carry locked-nucleic acid (LNA) oligonucleotides inhibiting microRNA-10b. Targeting moieties conjugated to the nanoparticles facilitate their accumulation at distant metastatic sites. Previously we have demonstrated the feasibility of the proposed approach. Delivery of the nanodrug to lymph nodes with already formed metastases resulted in arrest of metastatic progression by inhibiting tumor cell proliferation and causing apoptosis, which is a phenomenon that has not been described before. When treatment with the nanodrug was combined with a low-dose of conventional chemotherapy (doxorubicin), there was regression and permanent elimination of lymph node or lung metastases without relapse even after treatment was discontinued. Unlike conventional chemotherapies, this therapeutic protocol was not associated with animal morbidity/mortality. In the current application we propose to use the miR10b-inhibitory nanodrug in combination with low-dose chemotherapy (where necessary) for targeting breast cancer metastases in distant organs. Noninvasive imaging will be used to evaluate the delivery of the nanodrug. If successful, this approach could be a life- extending (and possibly, life saving) alternative for patients with advanced metastatic disease for whom salvage therapy is the only current option.